Merck (MRK) October weekly 103 straddle into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Merck (MRK) tops Q3 expectations on sustained growth in oncology and vaccine segments
October 26, 2023 9:26 AM EDTMerck (NYSE: MRK) reported earnings before the open Thursday, topping both profit and revenue consensus expectations.
The pharmaceutical company reported earnings of $2.13 per share, $0.18 better than the analyst estimate of $1.95, while revenue for the quarter came in at $16 billion, up 7% YoY and above the consensus estimate of $15.29 billion.
The company... More
